FIBP

Summary

FIBP (FGF1 intracellular binding protein, HGNC:3705) is a protein-coding gene on chromosome 11q13.1, encoding Acidic fibroblast growth factor intracellular-binding protein (O43427). May be involved in mitogenic function of FGF1.

Acidic fibroblast growth factor is mitogenic for a variety of different cell types and acts by stimulating mitogenesis or inducing morphological changes and differentiation. The FIBP protein is an intracellular protein that binds selectively to acidic fibroblast growth factor (aFGF). It is postulated that FIBP may be involved in the mitogenic action of aFGF. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 9158 — RefSeq curated summary.

At a glance

• Gene–disease (curated): tall stature-intellectual disability-renal anomalies syndrome (Strong, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 104 total — 1 pathogenic, 4 likely-pathogenic
• Phenotypes (HPO): 58
• Druggable target: yes
• MANE Select transcript: NM_004214

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3705
Approved symbol	FIBP
Name	FGF1 intracellular binding protein
Location	11q13.1
Locus type	gene with protein product
Status	Approved
Aliases	FGFIBP
Ensembl gene	ENSG00000172500
Ensembl biotype	protein_coding
OMIM	608296
Entrez	9158

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 9 protein_coding, 6 retained_intron, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000338369, ENST00000357519, ENST00000426652, ENST00000442885, ENST00000525765, ENST00000528937, ENST00000531115, ENST00000532229, ENST00000532679, ENST00000532934, ENST00000533037, ENST00000533045, ENST00000534032, ENST00000873727, ENST00000926949, ENST00000926950, ENST00000926951, ENST00000967693, ENST00000967694

RefSeq mRNA: 2 — MANE Select: NM_004214 NM_004214, NM_198897

CCDS: CCDS8118, CCDS8119

Canonical transcript exons

ENST00000357519 — 10 exons

Exon	Start	End
ENSE00000000132	65883740	65884043
ENSE00001380550	65888334	65888471
ENSE00003491324	65884935	65884998
ENSE00003520177	65885530	65885663
ENSE00003543689	65887934	65888132
ENSE00003545875	65885078	65885186
ENSE00003570357	65886322	65886422
ENSE00003618983	65884570	65884656
ENSE00003662533	65887600	65887726
ENSE00003690488	65884392	65884489

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 98.05.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 56.8476 / max 222.6898, expressed in 1822 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120722	56.8476	1822

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	98.05	gold quality
right frontal lobe	UBERON:0002810	97.38	gold quality
prefrontal cortex	UBERON:0000451	97.21	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.12	gold quality
apex of heart	UBERON:0002098	96.97	gold quality
cerebellar hemisphere	UBERON:0002245	96.95	gold quality
cerebellar cortex	UBERON:0002129	96.90	gold quality
ganglionic eminence	UBERON:0004023	96.89	gold quality
cortical plate	UBERON:0005343	96.80	gold quality
left testis	UBERON:0004533	96.72	gold quality
right testis	UBERON:0004534	96.62	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.38	gold quality
cingulate cortex	UBERON:0003027	96.31	gold quality
embryo	UBERON:0000922	96.28	gold quality
anterior cingulate cortex	UBERON:0009835	96.24	gold quality
cerebellum	UBERON:0002037	96.10	gold quality
amygdala	UBERON:0001876	96.01	gold quality
frontal cortex	UBERON:0001870	95.95	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.93	gold quality
neocortex	UBERON:0001950	95.86	gold quality
granulocyte	CL:0000094	95.84	gold quality
ventricular zone	UBERON:0003053	95.72	gold quality
right adrenal gland	UBERON:0001233	95.66	gold quality
right adrenal gland cortex	UBERON:0035827	95.60	gold quality
pons	UBERON:0000988	95.42	gold quality
endometrium epithelium	UBERON:0004811	95.35	gold quality
hypothalamus	UBERON:0001898	95.28	gold quality
mucosa of transverse colon	UBERON:0004991	95.26	gold quality
left adrenal gland	UBERON:0001234	95.24	gold quality
testis	UBERON:0000473	95.23	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	26.01
E-ANND-3	yes	8.33

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

9 targeting FIBP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-4456	97.50	64.88	1678

Literature-anchored findings (GeneRIF, showing 4)

• Data Show aFGF was expressed in regenerative hepatocytes, but not in fibroblasts, suggesting its role in promoting oxidative stress produced by hepatocytes may contribute to the development of fibrous bands in hepatic cirrhosis. (PMID:17497037)
• these findings provide convincing evidence implicating FIBP aberrations in the newly recognized overgrowth syndrome and expand the associated phenotypes to include possible Wilms tumor predisposition. (PMID:27183861)
• FIBP interacts with transcription factor STAT3 to induce EME1 expression and drive radioresistance in lung adenocarcinoma. (PMID:37564211)
• New cases of recently described Thauvin-Robinet-Faivre syndrome with a novel homozygous FIBP gene variant. (PMID:37876348)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	fibpa	ENSDARG00000016058
danio_rerio	fibpb	ENSDARG00000087666
mus_musculus	Fibp	ENSMUSG00000024911
rattus_norvegicus	Fibp	ENSRNOG00000020567
drosophila_melanogaster	Fibp	FBGN0036911

Protein

Protein identifiers

Acidic fibroblast growth factor intracellular-binding protein — O43427 (reviewed: O43427)

Alternative names: FGF-1 intracellular-binding protein

All UniProt accessions (4): E9PJW6, E9PSD3, O43427, H0YCE7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in mitogenic function of FGF1. May mediate with IER2 FGF-signaling in the establishment of laterality in the embryo.

Subunit / interactions. Binds to internalized FGF1; this interaction is increased in the presence of CSNKB, suggesting a possible cooperative interaction between CSNKB and FIBP in binding to FGF1.

Subcellular location. Nucleus. Endomembrane system.

Tissue specificity. Highly expressed in heart, skeletal muscle and pancreas. Expressed at lower levels in brain. Also found in placenta, liver and kidney.

Disease relevance. Thauvin-Robinet-Faivre syndrome (TROFAS) [MIM:617107] A rare autosomal recessive syndrome characterized by generalized overgrowth, developmental delay, learning disabilities, and variable congenital abnormalities including congenital heart defects, renal dysplasia, and skeletal defects. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
O43427-1	Long	yes
O43427-2	Short

RefSeq proteins (2): NP_004205, NP_942600 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008614	FIBP	Family

Pfam: PF05427

UniProt features (8 total): sequence variant 4, initiator methionine 1, chain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43427-F1	92.33	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 272 (showing top): MORF_MTA1, GOBP_PLATELET_ACTIVATION, MORF_HDAC2, chr11q13, GOBP_WOUND_HEALING, GOBP_CELL_CELL_ADHESION, GATA3_01, GOBP_RESPONSE_TO_FIBROBLAST_GROWTH_FACTOR, MORF_BUB3, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, GOBP_RESPONSE_TO_GROWTH_FACTOR, RYTTCCTG_ETS2_B, GOBP_FIBROBLAST_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, GOBP_HOMOTYPIC_CELL_CELL_ADHESION, GOBP_HEMOSTASIS

GO Biological Process (2): fibroblast growth factor receptor signaling pathway (GO:0008543), platelet aggregation (GO:0070527)

GO Molecular Function (1): fibroblast growth factor binding (GO:0017134)

GO Cellular Component (5): nucleus (GO:0005634), mitochondrion (GO:0005739), endomembrane system (GO:0012505), membrane (GO:0016020), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
cell surface receptor protein tyrosine kinase signaling pathway	1
cellular response to fibroblast growth factor stimulus	1
platelet activation	1
homotypic cell-cell adhesion	1
growth factor binding	1
cytoplasm	1
vacuole	1
plasma membrane	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

1326 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FIBP	FGF1	P05230	934
FIBP	C2CD5	Q86YS7	544
FIBP	IER2	Q9BTL4	418
FIBP	SIPA1	Q96FS4	364
FIBP	RFX2	P48378	351
FIBP	TBC1D25	Q3MII6	335
FIBP	CTSW	P56202	332
FIBP	IMP3	Q9NV31	328
FIBP	EIF1AD	Q8N9N8	293
FIBP	FGF11	Q92914	283
FIBP	KLK9	Q9UKQ9	280
FIBP	WDR3	Q9UNX4	276
FIBP	GNPDA1	P46926	271
FIBP	R3HCC1	Q9Y3T6	270
FIBP	ARFGAP2	Q8N6H7	267

IntAct

43 interactions, top by confidence:

A	B	Type	Score
CDK5	FIBP	psi-mi:“MI:0914”(association)	0.840
FIBP	CDK5	psi-mi:“MI:0914”(association)	0.840
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
DLK1	TCAF2	psi-mi:“MI:0914”(association)	0.530
CD44	PDPK1	psi-mi:“MI:0914”(association)	0.530
FIBP	DAPK1	psi-mi:“MI:0407”(direct interaction)	0.440
GSK3B	FIBP	psi-mi:“MI:0915”(physical association)	0.370
K8.1	EXOC5	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
SYT2	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
ZCCHC10	C1orf226	psi-mi:“MI:0914”(association)	0.350
IL13	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
CD6	CIBAR1	psi-mi:“MI:0914”(association)	0.350
AVPR1B	KLRG2	psi-mi:“MI:0914”(association)	0.350
EFNB1	KRBA1	psi-mi:“MI:0914”(association)	0.350
KCNE3	PIK3R2	psi-mi:“MI:0914”(association)	0.350
WDFY2	U2SURP	psi-mi:“MI:0914”(association)	0.350
DLL1	GNPAT	psi-mi:“MI:0914”(association)	0.350
SLC5A6	SLC31A1	psi-mi:“MI:0914”(association)	0.350
FIBP	DNM1L	psi-mi:“MI:0914”(association)	0.350
DLK1	PLPP3	psi-mi:“MI:0914”(association)	0.350
FIBP	AGRN	psi-mi:“MI:0914”(association)	0.350
LGALS3	SDCBP	psi-mi:“MI:0914”(association)	0.350
CFTR	UBA6	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (93): FIBP (Affinity Capture-MS), C2CD5 (Affinity Capture-MS), KIAA0195 (Affinity Capture-MS), CABLES2 (Affinity Capture-MS), CABLES1 (Affinity Capture-MS), CDK5 (Affinity Capture-MS), GRAMD1C (Affinity Capture-MS), FIBP (Affinity Capture-MS), FIBP (Affinity Capture-MS), FIBP (Affinity Capture-MS), CDK5 (Affinity Capture-MS), C2CD5 (Affinity Capture-MS), CABLES2 (Affinity Capture-MS), CABLES1 (Affinity Capture-MS), KIAA0195 (Affinity Capture-MS)

ESM2 similar proteins: A0A084B9Z7, A0A084B9Z8, A0A0A2JP58, A0A142C7A3, A0A179G9G5, A0A3G9HCC8, A0A455M2Z1, A0A481WNL0, A1Z8X3, A3EXH2, A8BQJ3, A9US33, C9K7F3, F4J8D3, L7WMF9, M1WCE9, O36385, O43427, P0A3V2, P0A3V3, P12798, P13157, P25203, P34335, P34596, P46018, P9WF00, Q0D1P5, Q28PE4, Q2U639, Q4IB89, Q4WVM7, Q5BHE2, Q6C229, Q6UDH7, Q70PP2, Q751J3, Q751N0, Q759Y1, Q75CM2

Diamond homologs: O43427, O46431, Q6T938, Q9JI19

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	4
Uncertain significance	64
Likely benign	11
Benign	5

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
3572869	FIBP, 7-BP DUP, NT412-3	Pathogenic
254242	NM_004214.5(FIBP):c.175_176insTAA (p.His59delinsLeuAsn)	Likely pathogenic
3064770	NM_004214.5(FIBP):c.558_559del (p.Gly187fs)	Likely pathogenic
3065901	NM_004214.5(FIBP):c.747del (p.His250fs)	Likely pathogenic
3347904	NM_004214.5(FIBP):c.513-1G>C	Likely pathogenic

SpliceAI

1745 predictions. Top by Δscore:

Variant	Effect	Δscore
11:65884386:GCTCA:G	donor_loss	1.0000
11:65884387:CTCAC:C	donor_loss	1.0000
11:65884388:TCA:T	donor_loss	1.0000
11:65884389:CAC:C	donor_loss	1.0000
11:65884486:CAAA:C	acceptor_gain	1.0000
11:65884488:AA:A	acceptor_gain	1.0000
11:65884490:C:CC	acceptor_gain	1.0000
11:65884491:T:C	acceptor_loss	1.0000
11:65884994:CCAGG:C	acceptor_gain	1.0000
11:65884995:CAGG:C	acceptor_gain	1.0000
11:65884995:CAGGC:C	acceptor_gain	1.0000
11:65884999:C:CC	acceptor_gain	1.0000
11:65885073:GTCAC:G	donor_loss	1.0000
11:65885077:CCT:C	donor_gain	1.0000
11:65885079:T:TA	donor_gain	1.0000
11:65885185:GT:G	acceptor_gain	1.0000
11:65885187:C:CC	acceptor_gain	1.0000
11:65885196:CA:C	acceptor_gain	1.0000
11:65885197:A:AC	acceptor_gain	1.0000
11:65885197:A:C	acceptor_gain	1.0000
11:65885662:CC:C	acceptor_gain	1.0000
11:65885663:CC:C	acceptor_gain	1.0000
11:65886317:CTCA:C	donor_loss	1.0000
11:65886318:TCA:T	donor_loss	1.0000
11:65886320:A:AG	donor_loss	1.0000
11:65886321:CCT:C	donor_loss	1.0000
11:65886418:TCAAA:T	acceptor_gain	1.0000
11:65886419:CAAA:C	acceptor_gain	1.0000
11:65886419:CAAAC:C	acceptor_gain	1.0000
11:65886420:AAA:A	acceptor_gain	1.0000

AlphaMissense

2361 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:65886408:T:A	K142N	1.000
11:65886408:T:G	K142N	1.000
11:65885548:A:G	W210R	0.999
11:65885548:A:T	W210R	0.999
11:65885629:G:T	R183S	0.999
11:65885646:A:T	V177D	0.999
11:65886403:A:T	V144D	0.999
11:65886410:T:C	K142E	0.999
11:65886414:G:C	N140K	0.999
11:65886414:G:T	N140K	0.999
11:65887603:T:A	R136S	0.999
11:65887603:T:G	R136S	0.999
11:65887604:C:G	R136T	0.999
11:65887680:T:C	K111E	0.999
11:65887685:C:T	G109D	0.999
11:65887686:C:G	G109R	0.999
11:65888352:A:G	W23R	0.999
11:65888352:A:T	W23R	0.999
11:65884628:G:T	A290D	0.998
11:65885568:G:T	A203D	0.998
11:65885628:C:G	R183P	0.998
11:65886398:T:C	K146E	0.998
11:65886406:C:G	R143P	0.998
11:65886409:T:A	K142I	0.998
11:65887607:C:G	R135P	0.998
11:65887652:A:G	L120P	0.998
11:65887660:C:A	K117N	0.998
11:65887660:C:G	K117N	0.998
11:65887667:C:T	G115D	0.998
11:65887671:T:C	K114E	0.998

dbSNP variants (sampled 300 via entrez): RS1000326802 (11:65888271 G>C), RS1000765021 (11:65884006 G>A), RS1001384988 (11:65888785 T>A), RS1001548379 (11:65885930 A>G), RS1001833034 (11:65888550 G>T), RS1002178705 (11:65886798 T>C), RS1002794877 (11:65889576 A>C,T), RS1002893945 (11:65884536 A>G,T), RS1003017807 (11:65883785 C>G), RS1003077274 (11:65889913 T>C), RS1003462978 (11:65890158 TC>T,TCC), RS1005188812 (11:65888678 C>A,T), RS1005734384 (11:65888538 A>G), RS1006899644 (11:65886615 C>A,T), RS1007226644 (11:65888248 A>C,G,T)

Disease associations

OMIM: gene MIM:608296 | disease phenotypes: MIM:617107

GenCC curated gene-disease

Disease	Classification	Inheritance
tall stature-intellectual disability-renal anomalies syndrome	Strong	Autosomal recessive

Mondo (3): tall stature-intellectual disability-renal anomalies syndrome (MONDO:0014918), coloboma (MONDO:0001476), learning disability (MONDO:0004681)

Orphanet (2): Tall stature-intellectual disability-renal anomalies syndrome (Orphanet:500095), OBSOLETE: Ocular coloboma (Orphanet:194)

HPO phenotypes

58 total (30 of 58 shown, HPO-id order):

HPO	Term
HP:0000003	Multicystic kidney dysplasia
HP:0000007	Autosomal recessive inheritance
HP:0000023	Inguinal hernia
HP:0000098	Tall stature
HP:0000105	Enlarged kidney
HP:0000107	Renal cyst
HP:0000110	Renal dysplasia
HP:0000158	Macroglossia
HP:0000256	Macrocephaly
HP:0000286	Epicanthus
HP:0000311	Round face
HP:0000316	Hypertelorism
HP:0000400	Macrotia
HP:0000407	Sensorineural hearing impairment
HP:0000411	Protruding ear
HP:0000480	Retinal coloboma
HP:0000483	Astigmatism
HP:0000486	Strabismus
HP:0000490	Deeply set eye
HP:0000494	Downslanted palpebral fissures
HP:0000518	Cataract
HP:0000589	Coloboma
HP:0000637	Long palpebral fissure
HP:0000750	Delayed speech and language development
HP:0001172	Abnormal thumb morphology
HP:0001176	Large hands
HP:0001249	Intellectual disability
HP:0001256	Mild intellectual disability
HP:0001263	Global developmental delay
HP:0001328	Specific learning disability

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002481_8	Acne (severe)	3.000000e-11
GCST004346_52	Psoriasis	7.000000e-09
GCST005537_77	Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	4.000000e-08
GCST009798_25	Asthma	2.000000e-09

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D003103	Coloboma	C11.250.110; C11.270.147; C16.131.384.282
D007859	Learning Disabilities	C10.597.606.150.550; C23.888.592.604.150.550; F03.625.374.188; F03.625.562

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066519 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.77	Kd	17.15	nM	CHEMBL5653589
7.52	ED50	30.07	nM	CHEMBL5653589
5.75	Kd	1790	nM	CHEMBL3752910
5.50	ED50	3140	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148386: Binding affinity to human FIBP incubated for 45 mins by Kinobead based pull down assay	kd	0.0171	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148386: Binding affinity to human FIBP incubated for 45 mins by Kinobead based pull down assay	kd	1.7904	uM

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	3
sodium arsenite	increases abundance, decreases expression, affects cotreatment	2
cobaltous chloride	decreases expression	2
aristolochic acid I	decreases expression	1
bisphenol A	affects expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
benzo(e)pyrene	decreases methylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
14-deoxy-11,12-didehydroandrographolide	decreases expression	1
jinfukang	increases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	decreases expression, increases abundance, affects cotreatment	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Coumestrol	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects expression	1
Hydrogen Peroxide	affects cotreatment, decreases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Methapyrilene	decreases methylation	1
Smoke	increases expression	1
Theophylline	affects cotreatment, decreases expression	1
Thiram	decreases expression	1
Tunicamycin	increases expression	1
Vitamin E	increases expression	1
Cadmium Chloride	decreases expression	1
tert-Butylhydroperoxide	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651428	Binding	Binding affinity to human FIBP incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1S6	Abcam HeLa FIBP KO	Cancer cell line	Female
CVCL_D9EX	Ubigene HEK293 FIBP KO	Transformed cell line	Female

Clinical trials (associated diseases)

51 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00254930	PHASE3	COMPLETED	A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children
NCT02964884	PHASE2	ACTIVE_NOT_RECRUITING	Interventions for Reading Disabilities in NF1
NCT00368004	Not specified	TERMINATED	Family Studies of Uveal Coloboma
NCT01778543	Not specified	RECRUITING	Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC)
NCT04833361	Not specified	COMPLETED	Potential Environmental Causes of Uveal Coloboma
NCT06293560	Not specified	RECRUITING	Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children
NCT00246792	PHASE2/PHASE3	UNKNOWN	Enhancing Self-Understanding and Social Integration of Middle School Students With Learning Disabilities
NCT01337232	PHASE1/PHASE2	COMPLETED	Building Complex Language
NCT00061412	Not specified	COMPLETED	Comprehensive Program to Improve Reading and Writing Skills in At-Risk and Dyslexic Children
NCT00240760	Not specified	UNKNOWN	Memantine and Down’s Syndrome
NCT00930449	Not specified	COMPLETED	Effects Of A Computerized Working Memory Training Program On Attention, Working Memory, And Academics, In Adolescents With Severe ADHD/LD
NCT01032369	Not specified	UNKNOWN	The Additive Effect of Cognitive Behavioral Treatment (CBT) to Conventional Weight Loss Intervention Program for Young Adults With Intellectual Disabilities
NCT01426451	Not specified	COMPLETED	Assessment of a Drama Workshop Program for Immigrant and Refugee Adolescents
NCT01652651	Not specified	UNKNOWN	Risk and Resilience Factors in Learning Disabilities Population
NCT01818778	Not specified	COMPLETED	The Efficacy of Using Volunteers to Implement a Cognitive Stimulation Program in Two Long-Term Care Homes
NCT02160886	Not specified	COMPLETED	Effects of a Task Oriented Intervention With Two Goal-setting Approaches
NCT02227381	Not specified	COMPLETED	Action Medical Research
NCT02345512	Not specified	COMPLETED	Investigating the Clinical and Cost Effectiveness of Lycra Splinting
NCT02797301	Not specified	COMPLETED	A Computerised Test for Assessing the Early Reading Skills
NCT02827396	Not specified	COMPLETED	Effectiveness of a Training Intervention on Mental Health of Parents for Intellectually Disabled Children in Malawi
NCT02919215	Not specified	TERMINATED	Teacher Help for Children and Youth With Mental Health Disorders
NCT02970825	Not specified	UNKNOWN	Move and Feel Good : Effects of Intensive Physical Training on Brain Plasticity, Cognition and Psychological Well-being.
NCT03255499	Not specified	UNKNOWN	Efficacy of the MovinCog Intervention in Children
NCT03522337	Not specified	COMPLETED	Oral Health Promotion Among Preschool Children With Special Needs
NCT03626272	Not specified	UNKNOWN	Effects of the in Situ Simulation to Competencies in Cardiopulmonary Resuscitation in the Nursing Team.
NCT03695068	Not specified	UNKNOWN	Efficacy of a Two-Year Intensive Reading Intervention for Middle School English Learners With Reading Difficulties
NCT03717922	Not specified	COMPLETED	Low Intensity Focused Ultrasound for Learning and Memory and Emotion Regulation
NCT03846271	Not specified	UNKNOWN	Effects of Oxytocin on Reinforcement Learning
NCT04048213	Not specified	UNKNOWN	The Becoming of Children With Doose Syndrome
NCT04178421	Not specified	COMPLETED	Computerized Eye-tracking Attention Training for Children With Special Needs
NCT04280367	Not specified	COMPLETED	Learning and Executive Function Disorders in Children and Psychosis Risk at Adult-age
NCT04325282	Not specified	COMPLETED	Transcranial Magnetic Stimulation for BECTS
NCT04365894	Not specified	COMPLETED	Affective Learning in Disabled Health Training
NCT04583332	Not specified	COMPLETED	Efficacy of AAC for Functional Communication
NCT05154721	Not specified	COMPLETED	Rhythm Training of a Serious Game on the Reading Skills of Children w/ a Specific Learning Disorder Impacting Reading
NCT05201534	Not specified	RECRUITING	Interventions in Mathematics and Cognitive Skills
NCT05476133	Not specified	COMPLETED	Application of a Training Program for Executive Functions in a Sample of Egyptian Children With Learning Disorder
NCT05686473	Not specified	RECRUITING	Psychoeducation of Parents to Children With FASD
NCT05767242	Not specified	RECRUITING	Early Neurophysiological Markers of Language Impairments
NCT05803278	Not specified	COMPLETED	Online Screening and Empowerment Program for Children With SLD